NPXe Files Voluntary Chapter 11 to Implement 363 Asset Sale
NPXe Limited (“NPXe”), a Phase III pharmaceutical and drug delivery device company developing XENEX™ (xenon gas for inhalation) for neuro- and cardio-protection and improvement in survival for post-cardiac arrest syndrome (PCAS) patients, announced that it has filed a voluntary petition to reorganize under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for
NPXe Files Voluntary Chapter 11 to Implement 363 Asset Sale Read More »
